Found: 20
Select item for more details and to access through your institution.
Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
- Published in:
- Journal of Medical Virology, 2020, v. 92, n. 8, p. 1370, doi. 10.1002/jmv.25837
- By:
- Publication type:
- Article
Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
- Published in:
- Journal of Medical Virology, 2020, v. 92, n. 3, p. 329, doi. 10.1002/jmv.25644
- By:
- Publication type:
- Article
Switching from combination therapy with entecavir hydrate plus tenofovir alafenamide fumarate to tenofovir alafenamide fumarate monotherapy in patients with chronic hepatitis B based on nucleotide sequences of hepatitis B virus pregenome RNA.
- Published in:
- Hepatology Research, 2024, v. 54, n. 10, p. 877, doi. 10.1111/hepr.14036
- By:
- Publication type:
- Article
Significance of portal venous blood flow as a factor to determine liver function in patients with decompensated cirrhosis due to hepatitis C virus infection following achievement of sustained viral response by sofosbuvir plus velpatasvir.
- Published in:
- Hepatology Research, 2023, v. 53, n. 9, p. 815, doi. 10.1111/hepr.13926
- By:
- Publication type:
- Article
Significance of furosemide in patients with cirrhosis treated with or without zinc acetate hydrate supplementation.
- Published in:
- Hepatology Research, 2022, v. 52, n. 5, p. 449, doi. 10.1111/hepr.13751
- By:
- Publication type:
- Article
Furosemide as a factor to deteriorate therapeutic efficacy of tolvaptan in patients with decompensated cirrhosis.
- Published in:
- Hepatology Research, 2020, v. 50, n. 12, p. 1355, doi. 10.1111/hepr.13566
- By:
- Publication type:
- Article
Furosemide as a factor to deteriorate therapeutic efficacy of rifaximin in patients with decompensated cirrhosis.
- Published in:
- Hepatology Research, 2020, v. 50, n. 11, p. 1264, doi. 10.1111/hepr.13564
- By:
- Publication type:
- Article
Involvement of portosystemic shunts in impaired improvement of liver function after direct‐acting antiviral therapies in cirrhotic patients with hepatitis C virus.
- Published in:
- Hepatology Research, 2020, v. 50, n. 4, p. 512, doi. 10.1111/hepr.13471
- By:
- Publication type:
- Article
A case of genotype‐3b hepatitis C virus in which the whole genome was successfully analyzed using third‐generation nanopore sequencing.
- Published in:
- Hepatology Research, 2019, v. 49, n. 9, p. 1083, doi. 10.1111/hepr.13339
- By:
- Publication type:
- Article
Retreatment with sofosbuvir/ledipasvir with or without lead‐in interferon‐β injections in patients infected with genotype 1b hepatitis C virus after unsuccessful daclatasvir/asunaprevir therapy.
- Published in:
- Hepatology Research, 2018, v. 48, n. 4, p. 233, doi. 10.1111/hepr.12980
- By:
- Publication type:
- Article
Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct‐acting antivirals.
- Published in:
- Hepatology Research, 2018, v. 48, n. 3, p. E372, doi. 10.1111/hepr.12977
- By:
- Publication type:
- Article
'Reversi-type virologic failure' involved in the development of non-structural protein 5A resistance-associated variants (RAVs) in patients with genotype 1b hepatitis C carrying no signature RAVs at baseline.
- Published in:
- Hepatology Research, 2017, v. 47, n. 13, p. 1397, doi. 10.1111/hepr.12882
- By:
- Publication type:
- Article
Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two-hit mechanism.
- Published in:
- Hepatology Research, 2016, v. 46, n. 12, p. 1234, doi. 10.1111/hepr.12673
- By:
- Publication type:
- Article
Novel hepatitis B virus strain developing due to recombination between genotypes H and B strains isolated from a Japanese patient.
- Published in:
- Hepatology Research, 2014, v. 44, n. 11, p. 1130, doi. 10.1111/hepr.12238
- By:
- Publication type:
- Article
A Novel Simple Assay System to Quantify the Percent HCV-RNA Levels of NS5A Y93H Mutant Strains and Y93 Wild-Type Strains Relative to the Total HCV-RNA Levels to Determine the Indication for Antiviral Therapy with NS5A Inhibitors.
- Published in:
- PLoS ONE, 2014, v. 9, n. 11, p. 1, doi. 10.1371/journal.pone.0112647
- By:
- Publication type:
- Article
NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Sequential therapy consisting of glucocorticoid infusions followed by granulocyte-monocyte absorptive apheresis in patients with severe alcoholic hepatitis.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog.
- Published in:
- PLoS ONE, 2022, v. 17, n. 2, p. 1, doi. 10.1371/journal.pone.0262764
- By:
- Publication type:
- Article
Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy.
- Published in:
- PLoS ONE, 2018, v. 13, n. 10, p. 1, doi. 10.1371/journal.pone.0205600
- By:
- Publication type:
- Article